Rapport Therapeutics, Common Stock Performance
| RAPP Stock | 30.34 0.30 0.98% |
Rapport Therapeutics, has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 1.31, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rapport Therapeutics, will likely underperform. Rapport Therapeutics, right now holds a risk of 3.58%. Please check Rapport Therapeutics, value at risk, as well as the relationship between the skewness and day median price , to decide if Rapport Therapeutics, will be following its historical price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Rapport Therapeutics, Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Rapport Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Actual Historical Performance (%)
One Day Return (0.96) | Five Day Return (0.98) | Year To Date Return 64.98 | Ten Year Return 45.87 | All Time Return 45.87 |
1 | Weiss Ratings Reaffirms Sell Rating for Rapport Therapeutics | 10/09/2025 |
2 | Disposition of 755 shares by Ceesay Abraham of Rapport Therapeutics, at 26.1721 subject to Rule 16b-3 | 10/15/2025 |
3 | Does Rapport Therapeutics Rising Losses and Improving Per-Share Results Reveal a Shift in RAPPs Strategy | 11/17/2025 |
4 | Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeti... | 11/25/2025 |
5 | Disposition of 5000 shares by Cheryl Gault of Rapport Therapeutics, at 1.8 subject to Rule 16b-3 | 11/26/2025 |
6 | Wall Street Analysts See a 74.99 percent Upside in Rapport Therapeutics, Inc. Can the Stock Really Move This High | 11/28/2025 |
7 | Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219s Clinical Response in Patients with Focal O... | 12/05/2025 |
8 | Rapport Therapeutics, Inc. Is Up 9.03 percent in One Week What You Should Know | 12/08/2025 |
9 | Rapport Therapeutics Shapes Focused Clinical Neuroscience Programs - Kalkine Media | 12/12/2025 |
10 | Rapport Therapeutics Upgraded at Wall Street Zen | 12/17/2025 |
11 | How RAP-219 Phase 2a Data and 2026 Phase 3 Plans At Rapport Therapeutics Has Changed Its Investment Story | 12/19/2025 |
12 | Rapport Therapeutics Valuation Check After Joining the SP Pharmaceuticals Select Industry Index | 12/23/2025 |
| Begin Period Cash Flow | 70.3 M | |
| Total Cashflows From Investing Activities | -170.1 M |
Rapport Therapeutics, Relative Risk vs. Return Landscape
If you would invest 2,854 in Rapport Therapeutics, Common on October 2, 2025 and sell it today you would earn a total of 210.00 from holding Rapport Therapeutics, Common or generate 7.36% return on investment over 90 days. Rapport Therapeutics, Common is currently generating 0.1757% in daily expected returns and assumes 3.5802% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Rapport, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Rapport Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rapport Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Rapport Therapeutics, Common, and traders can use it to determine the average amount a Rapport Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0491
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | RAPP | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Rapport Therapeutics, is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Rapport Therapeutics, by adding it to a well-diversified portfolio.
Rapport Therapeutics, Fundamentals Growth
Rapport Stock prices reflect investors' perceptions of the future prospects and financial health of Rapport Therapeutics,, and Rapport Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Rapport Stock performance.
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.16 | ||||
| Current Valuation | 958.94 M | ||||
| Shares Outstanding | 47.66 M | ||||
| Price To Book | 2.85 X | ||||
| EBITDA | (77.47 M) | ||||
| Net Income | (78.31 M) | ||||
| Total Debt | 1.48 M | ||||
| Book Value Per Share | 10.74 X | ||||
| Cash Flow From Operations | (64.83 M) | ||||
| Earnings Per Share | (2.27) X | ||||
| Market Capitalization | 1.46 B | ||||
| Total Asset | 314.93 M | ||||
| Retained Earnings | (123.75 M) | ||||
| Working Capital | 301.04 M | ||||
About Rapport Therapeutics, Performance
Assessing Rapport Therapeutics,'s fundamental ratios provides investors with valuable insights into Rapport Therapeutics,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Rapport Therapeutics, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.27) | (0.28) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.26) | (0.24) |
Things to note about Rapport Therapeutics, performance evaluation
Checking the ongoing alerts about Rapport Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Rapport Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Rapport Therapeutics, had very high historical volatility over the last 90 days | |
| Rapport Therapeutics, has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (78.31 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Rapport Therapeutics, generates negative cash flow from operations | |
| Rapport Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: Rapport Therapeutics Valuation Check After Joining the SP Pharmaceuticals Select Industry Index |
- Analyzing Rapport Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Rapport Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Rapport Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Rapport Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Rapport Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Rapport Therapeutics,'s stock. These opinions can provide insight into Rapport Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.